Merck and Pfizer have received a major boost to their immune-oncology alliance with a second FDA Breakthrough Therapy Designation for Bavencio, this time in combination with Pfizer’s Inlyta.

Recarbrio – which based on established antibiotic combination imipenem/cilastatin with Merck’s new beta-lactamase ... director for the Office of Antimicrobial Products at the FDA, said that ...

Merck MRK decided to discontinue two clinical development programs, namely KeyVibe and KEYFORM, which are evaluating its investigational cancer drugs vibostolimab and favezelimab, respectively.

The companies are conducting pivotal phase III studies on V940, in combination with ... generate significant revenues for Merck over the long term. Both the products are witnessing a strong ...

In partnership with Moderna MRNA, Merck is developing a personalized mRNA therapeutic cancer vaccine (V940/mRNA-4157) in combination with Keytruda for patients with certain types of melanoma and ...